Skip to main content
. Author manuscript; available in PMC: 2019 Aug 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2018 Mar 27;24(8):1581–1589. doi: 10.1016/j.bbmt.2018.03.019

Table 2.

Overall Summary of Treatment-emergent Adverse Events, Overall and by Dose Group

Dose Group
Patients with at least 1: 3×105 (N=3)
n (%)		 1×106 (N=3)
n (%)		 3×106 (N=6)
n (%)		 Total (N=12)
n (%)
TEAE 3(100) 3 (100) 6 (100) 12 (100)
Study drug-related TEAE 3 (100) 2 (67) 4 (67) 9 (75)
Dose-limiting toxicities 0 0 0 0
TEAE representing an infusion-related toxicity 0 0 0 0
Grade 3 TEAE 1 (33) 1 (33) 1 (17) 3 (25)
Grade 4 TEAE 1 (33) 1 (33) 3 (50) 5 (42)
Grade 5 TEAE (ie, TEAE resulting in death) 0 0 1 (17) 1 (8)
SAE 1 (33) 1 (33) 3 (50) 5 (42)
TEAE leading to study discontinuation 0 0 1 (17) 1 (8)